



NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230MH1990PLC058071

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2016

(Rs. In Lacs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2016*	31.03.2016	30.06.2015	31.03.2016
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income from Operations				
	(a) Net Sales/Income from Operations	417.78	515.73	367.14	1885.63
	(b) Other Operating Income	0.11	0.00	0.00	29.68
	Total Income From Operations (Net)	417.89	515.73	367.14	1915.31
2	Expenses				
	a. Cost of Materials Consumed	192.29	234.11	202.79	959.36
	b. Purchase of Stock in Trade	0.00	0.00	0.00	0.00
	c. Changes in Inventories of Finished Goods, work in Progress and stock in trade	7.67	-29.39	-48.83	-29.39
	d. Employee Benfit Expenses	116.49	123.63	100.56	483.53
	e. Depreciation and Amortisation Expense	14.50	-34.59	31.47	59.81
	f. Loss/Gain on Foreign Exchange Transactions	0.00	0.00	-0.45	0.00
	g. Other expenditure	97.48	114.13	91.06	388.69
	Total Expenses	428.43	407.89	376.60	1862.00
3	Profit/ (Loss) from operations before Other Income, Finance Costs and exceptional items (1-2)	-10.54	107.84	-9.46	53.31
4	Other Income	0.07	-9.28	4.11	0.00
5	Profit/ (Loss) from Ordinary activities before Finance Costs and Exceptional Items (3+4)	-10.47	98.56	-5.35	53.31
6	Finance Costs	12.15	10.63	13.16	67.03
7	Profit/ (Loss) from Ordinary activities after Finance Costs but before Exceptional Items (5-6)	-22.62	87.93	-18.51	-13.72
8	Exceptional Items	0.00	0.00	0.00	0.00
9	Profit/ (Loss) from Ordinary activities before Tax	-22.62	87.93	-18.51	-13.72
10	Tax Expense				
	Less: Provision for Current Tax	0.00	0.00	0.00	0.00
	Add Provision for Deferred Tax Assets	0.00	17.50	0.00	17.50
11	Net Profit / (Loss) for the period	-22.62	105.43	-18.51	3.78
12	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58
13	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00
14	Basic and Diluted EPS before & after extraordinary items	-0.23	1.05	-0.19	0.04

#Notes

- The above results were reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on 11th August, 2016.
- The Company is having one segment only and therefore Segmental Reporting is not applicable.
- There are no exceptional/ extraordinary items during the quarter ended 30.06.2016.
- Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures.

For, Norris Medicines Ltd

Vimal D. Shah
Managing Director

Date : 11.08.2016

Place : Ankleshwar

Review Report to the Board of Directors
Norris Medicines Limited
Ankleshwar.

We have reviewed the accompanying statement of unaudited financial results of **Norris Medicines Limited** ("the company") for the period ended 30th June, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : BHARUCH

Date : 11th August, 2016

232, Rangoli Complex,
Station Road,
Bharuch – 392 001
Gujarat.



For, **MINU MODI & CO.**

Chartered Accountants

CA MINU MODI

Proprietor

M. No. 100289

(Firm Reg. No. 119948W)